Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Halfmann

Showing results (21-30 of 111) with videos related to

Pageof 12
Sort By:
Cell Reports|February 9, 2022
Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster modelPeter J Halfmann, Makoto Kuroda, Tammy Armbrust, et al.
Critical Care Nurse|April 1, 1991
Fluid volume dynamicsA M Jones, M J Moseley, S J Halfmann, et al.
Nature Communications|February 12, 2024
Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccinePeter J Halfmann, Kathryn Loeffler, Augustine Duffy, et al.
Npj Viruses|July 29, 2025
Merbecovirus S2 subunit vaccines elicit cross reactive antibodies and provide partial protection against MERS coronavirusPeter J Halfmann, Jeong Soo Lee, Augustine Duffy, et al.
Vaccine|February 22, 2025
Correction to "Recombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2" [Vaccine 22 (41) (2023) 6025-6035]Shiho Chiba, Peter J Halfmann, Shun Iida, et al.
Emerging Infectious Diseases|January 26, 2021
Protective Immunity and Persistent Lung Sequelae in Domestic Cats after SARS-CoV-2 InfectionShiho Chiba, Peter J Halfmann, Masato Hatta, et al.
Vaccine|August 27, 2023
Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2Shiho Chiba, Peter J Halfmann, Shun Iida, et al.
The Journal of Infectious Diseases|June 28, 2023
The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in FerretsPeter J Halfmann, Viktoriya Borisevich, Corri B Levine, et al.
Nature Communications|May 13, 2025
SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platformMakoto Kuroda, Peter J Halfmann, Ryuta Uraki, et al.
Cell Reports|April 14, 2022
Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamstersPeter J Halfmann, Makoto Kuroda, Tadashi Maemura, et al.
Pageof 12

Showing results (21-30 of 111) with videos related to

Sort By:
Pageof 12
Cell Reports|February 9, 2022
Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster modelPeter J Halfmann, Makoto Kuroda, Tammy Armbrust, et al.
Critical Care Nurse|April 1, 1991
Fluid volume dynamicsA M Jones, M J Moseley, S J Halfmann, et al.
Nature Communications|February 12, 2024
Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccinePeter J Halfmann, Kathryn Loeffler, Augustine Duffy, et al.
Npj Viruses|July 29, 2025
Merbecovirus S2 subunit vaccines elicit cross reactive antibodies and provide partial protection against MERS coronavirusPeter J Halfmann, Jeong Soo Lee, Augustine Duffy, et al.
Vaccine|February 22, 2025
Correction to "Recombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2" [Vaccine 22 (41) (2023) 6025-6035]Shiho Chiba, Peter J Halfmann, Shun Iida, et al.
Emerging Infectious Diseases|January 26, 2021
Protective Immunity and Persistent Lung Sequelae in Domestic Cats after SARS-CoV-2 InfectionShiho Chiba, Peter J Halfmann, Masato Hatta, et al.
Vaccine|August 27, 2023
Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2Shiho Chiba, Peter J Halfmann, Shun Iida, et al.
The Journal of Infectious Diseases|June 28, 2023
The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in FerretsPeter J Halfmann, Viktoriya Borisevich, Corri B Levine, et al.
Nature Communications|May 13, 2025
SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platformMakoto Kuroda, Peter J Halfmann, Ryuta Uraki, et al.
Cell Reports|April 14, 2022
Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamstersPeter J Halfmann, Makoto Kuroda, Tadashi Maemura, et al.
Pageof 12